La chaîne d'options affiche les données clés des options sur actions de Quantum-Si à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Quantum-Si..

Quantum-Si (NASDAQ:QSI) Stock, Chaîne d'Options

QUANTUM-SI INC

Quantum-Si

Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si Inc

WisdomTree U.S. Short Term Corporate Bond Fund

Pacer Metaurus Nasdaq 100 Dividend Multiplier 600 ETF

News

Guidance

SGBX

Safe & Green Holdings Provides Corporate Update; To Evaluate High-Value Partnerships And Acquisitions Across US Energy Productio, Sustainable Technologies And Modular Construction Solutions

Today, Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) subsidiary Lockheed Martin España S.A. signed a significant industrial cooperation agreement with the Spanish Ministry of Defense, providing the Spanish defense industry with increased engineering and production capability. This agreement leads to the opportunity for Spanish Industry to compete for the production of Patriot Advanced Capability-3 (PAC-3) Missile Segment Enhancement (MSE) components. This agreement marks a major milestone in the company's efforts to strengthen defense supply chains, harnessing the best of Spanish, U.S. and greater European industry.
The agreement, signed during the International Defence and Security Exhibition of Spain, (FEINDEF) outlines a framework for future collaboration on industrial development projects in Spain with leading Spanish defense technology firms Sener and Oesía-Tecnobit. Sener will design and develop PAC-3 MSE actuators based on Lockheed Martin specifications and Oesía Tecnobit will produce specialized PAC-3 MSE cables and harnesses. Lockheed Martin España has been working closely with these companies since 2023.

Lockheed Martin Expands Industrial Cooperation In Spain With New PAC-3 MSE Agreement

Citigroup analyst Geoff Meacham upgrades Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) from Neutral to Buy and raises the price target from $600 to $700.

Upgrades

Price Target

Analyst Ratings

REGN

Citigroup Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $700

Saudi Arabian Mining Company ("Maaden" or the "Company", 1211 on the Saudi Exchange), one of the world's fastest growing mining companies, has signed an agreement with MP Materials Corp ("MP Materials") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>), the American fully integrated rare earth producer, to explore opportunities to establish a fully integrated, end-to-end rare earth supply chain.
A Memorandum of Understanding (MoU) was signed on the sideline of the U.S.-Saudi Investment Forum 2025, taking place in Riyadh.
This agreement combines world-class exploration and processing expertise to advance and de-risk the development of potential Rare Earth Element (REE) deposits across Saudi Arabia as it continues to position itself as a world-leading player in the critical minerals sector. Maaden and MP Materials aim to explore opportunities to jointly develop a vertically integrated rare earth supply chain in Saudi Arabia, including mining, separation, refining, and magnet production, to drive industrial depth and create value for downstream sectors.
 &nbsp;
 &nbsp;

Saudi Arabian Mining Agrees With MP Materials To Explore Opportunities To Establish Fully Integrated, End-To-End Rare Earth Supply Chain

Billionaire hedge-fund boss Bill Ackman hailed Sen. Ted Cruz's proposal to give every newborn American a $1,000 investment account, posting on X: "I have been a fan of this idea for years. It is great to see it finally happening."
What Happened: Ackman's praise followed Cruz's CNBC <a href="https://www.cnbc.com/video/2025/05/13/sen-ted-cruz-on-invest-america-act-allows-kids-to-climb-the-economic-ladder-much-faster.html">clip</a> touting the Invest America Act, which the Texas Republican says will &#8220;create an investment account for every newborn American child that the federal government will seed with $1,000.&#8221; A House version surfaced Tuesday in the Ways and Means Committee's budget package, signaling the plan's first real legislative traction.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I have been a fan of this idea for years. It is great to see it finally happening. <a href="https://t.co/kdSZkrch8X">https://t.co/kdSZkrch8X</a> <a href="https://t.co/AtspxvcVE2">https://t.co/AtspxvcVE2</a>
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1922391975002566835?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See also: <a href="https://www.benzinga.com/general/entertainment/25/05/45403511/bill-gates-predicted-in-1995-that-one-day-computers-might-think-on-their-own-but-called-it-a-scary-thought-and-admitted-no-one-knows-when-that-will-happen">Bill Gates Once Warned That Computers Might Eventually Think On Their Own—But Admitted It Was A &#8216;Scary Thought&#8217; That &#8216;No One Knows When That Will Happen&#8217;</a>
Under the bill, each account would track a low-cost S&amp;P 500 index fund. Relatives could add up to $5,000 a year, and the balance could be tapped at 18 for college, a first home or a business launch. Cruz's office estimates the nest egg could hit roughly $170,000 by adulthood, assuming a 7 percent annual return.
What To Know: Backers frame the idea as program that would broaden stock ownership and "cultivate a generation of capitalists," in Cruz's words.
Critics, as per a <a href="https://www.houstonchronicle.com/politics/texas/article/ted-cruz-tax-cut-plan-20324854.php">report</a> by the Houston Chronicle, counter that seeding every baby — about 3.6 million births a year — could cost billions and lacks income caps, raising deficit alarms. House Republicans rebranded the accounts "MAGA Savings" in their draft, reflecting former President Donald Trump's push to add pro-growth sweeteners to a broader 2017 tax-cut extension.
Even with Ackman's Wall Street clout behind it, the measure faces a steep climb in a divided Congress. But the financier's endorsement echoes a rare bipartisan appeal of giving every American a personal stake in the market from day one.
Read next: <a href="https://www.benzinga.com/25/05/45404338/wall-streets-most-accurate-analysts-spotlight-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a>

Education

Personal Finance

General

Sen. Ted Cruz Wants To Give Americans $1,000 At Birth To Invest, Bill Ackman Says He's 'Been A Fan Of This Idea For Years'

ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 11.76 percent increase over losses of $(0.17) per share from the same period last year. The company reported $1.55 million in sales this quarter.

Earnings

Earnings Beats

ATAI

ATAI Life Sciences Q1 EPS $(0.15) Beats $(0.18) Estimate, Sales $1.55M

Citigroup analyst Geoff Meacham downgrades AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) from Buy to Neutral and lowers the price target from $210 to $205.

Downgrades

ABBV

Citigroup Downgrades AbbVie to Neutral, Lowers Price Target to $205

Earnings Outlook
The Company has raised its full-year 2025 guidance for new transaction funding outside of the Lennar Master Program to $1.5 billion, up from the previously announced $1 billion, driven by heightened demand.
Accordingly, the Company has also increased year-end quarterly earnings per share run-rate to a range of $0.69 to $0.71.

Raised Its FY25 Guidance For New Transaction Funding Outside Of The Lennar Master Program To $1.5B, Up From The Previously Announced $1B, Driven By Heightened Demand;  Increased Year-End Quarterly Earnings Per Share Run-Rate To A Range Of $0.69 To $0.71.

Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable safety profile
SEATTLE, May 14, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4427161-1&amp;h=1470666501&amp;u=https%3A%2F%2Fatossatherapeutics.com%2F&amp;a=Atossa+Therapeutics%2C+Inc.">Atossa Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today reported full results from the Phase 2 Endocrine Optimization Pilot (EOP) sub‑study within the I‑SPY 2 TRIAL evaluating low‑dose oral (Z)‑endoxifen (10 mg daily) as a neoadjuvant treatment in 20 women with stage II/III estrogen‑receptor–positive (ER+), HER2‑negative breast cancer.

ATOS

Atossa Therapeutics Reports Full Results From Phase 2 EOP Sub‑Study Within I‑SPY 2 Trial Evaluating Low‑Dose Oral (Z)‑Endoxifen As Neoadjuvant Treatment In 20 Women With Stage II/III ER+, HER2‑Negative Breast Cancer

Millrose Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRP#NYSE">MRP</a>) reported quarterly earnings of $0.39 per share.

Millrose Properties Q1 EPS $0.39

Antalpha Platform Holding Company ("Antalpha" or the "Company") today announced the pricing of its initial public offering of 3,850,000 ordinary shares at a price to the public of $12.80 per ordinary share. The ordinary shares have been approved for listing and are expected to begin trading on the Nasdaq Global Market on May 14, 2025, under the ticker symbol "ANTA." The offering is expected to close on May 15, 2025, subject to customary closing conditions.
Antalpha has granted the underwriters a 30-day option to purchase an additional 577,500 ordinary shares to cover over-allotments in connection with the offering.

IPOs

ANTA

Antalpha Announces Pricing Of Initial Public Offering Of 3.85M Shares At A Price Of $12.80 Per Share

Citigroup analyst Arthur Truslove downgrades UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>) from Buy to Neutral and raises the price target from $60.5 to $71.

Citigroup Downgrades UL Solutions to Neutral, Raises Price Target to $71

IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.38) by 10.53 percent. This is a 13.33 percent decrease over losses of $(0.30) per share from the same period last year.

IOBT

IO Biotech Q1 EPS $(0.34) Beats $(0.38) Estimate

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the communication services sector.
<h3 class="wp-block-heading">Shutterstock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSTK#NYSE">SSTK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.83%</li>
<li>JMP Securities analyst Andrew Boone reiterated a Market Perform rating on May 5, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Needham analyst Bernie McTernan maintained a Buy rating and cut the price target from $45 to $30 on March 7, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On May 2, the company posted downbeat quarterly results</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">SSTK news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="896" height="811" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156.png" alt="" class="wp-image-914631" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156.png 896w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156-768x695.png 768w" sizes="(max-width: 896px) 100vw, 896px" /></a></figure>
<h3 class="wp-block-heading">Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.35%</li>
<li>Tigress Financial analyst Ivan Feinseth maintained a Buy rating and raised the price target from $55 to $56 on April 28, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Scotiabank analyst Maher Yaghi maintained a Sector Perform rating and increased the price target from $48.5 to $49 on April 23, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On May 13, Verizon announced a $5 billion commitment to continue investing in America and supporting small businesses.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">latest VZ news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="907" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157.png" alt="" class="wp-image-914632" style="width:698px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157-768x709.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Nexstar Media Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.27%</li>
<li>Benchmark analyst Daniel Kurnos maintained a Buy rating and raised the price target from $215 to $220 on May 9, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Wells Fargo analyst Steven Cahall maintained an Overweight rating and cut the price target from $216 to $200 on May 1, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On May 8, Nexstar Media Group reported better-than-expected first-quarter EPS results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest NXST <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="895" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158.png" alt="" class="wp-image-914635" style="width:671px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158.png 895w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158-768x709.png 768w" sizes="(max-width: 895px) 100vw, 895px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

Trading Ideas

NXST

SSTK

Wall Street's Most Accurate Analysts Spotlight On 3 Tech And Telecom Stocks Delivering High-Dividend Yields

Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) affirms FY2025 sales outlook from $30.00 million to $30.00 million vs $40.20 million estimate.

ALUR

Allurion Technologies Affirms FY2025 Sales Guidance of $30.00M vs $40.20M Est

WIIM

IXHL

Incannex Healthcare shares are trading higher after the company completed patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study of IHL-42X for obstructive sleep apnea.

Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) reported quarterly losses of $(0.66) per share. This is a 1.49 percent increase over losses of $(0.67) per share from the same period last year. The company reported $162.46 thousand in sales this quarter. This is a 57.31 percent decrease over sales of $380.57 thousand the same period last year.

APRE

Aprea Therapeutics Q1 EPS $(0.66) Up From $(0.67) YoY, Sales $162.46K Down From $380.57K YoY

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.35) by 31.43 percent. This is a 85.37 percent increase over losses of $(1.64) per share from the same period last year.

BNTC

Benitec Biopharma Q3 EPS $(0.24) Beats $(0.35) Estimate

Kalaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLRS#NASDAQ">KLRS</a>) reported quarterly losses of $(2.52) per share which missed the analyst consensus estimate of $(1.17) by 115.38 percent. This is a 3.08 percent increase over losses of $(2.60) per share from the same period last year.

Earnings Misses

KLRS

Kalaris Therapeutics Q1 EPS $(2.52) Misses $(1.17) Estimate

<a href="https://www.globenewswire.com/Tracker?data=VFi76zOPFziMSR2L83lWTcD9X8IU9_hdqO5B40n9RLxP2qqmSR1JF-raa6_Ik_4j4qJiYG-antKeH0DlGMEp7fyTIIWVfSorVwAMNQP3aCc=">Enphase Energy, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that homeowners in all of New York's major investor-owned electric utility service territories who install Enphase IQ&#xAE; Batteries can now qualify to enroll in the NYSERDA New York Battery Incentive Program. Qualifying homeowners can receive an upfront payment of up to $6,250 through the program.
Homeowners in the Central Hudson, ConEd, NYSEG, National Grid, Orange and Rockland, and Rochester G&amp;E service areas could receive the upfront incentive. Homeowners in the ConEd territory of New York City and Westchester County are eligible for an upfront incentive of $250/kWh, capped at $6,250 per site. For example, customers who install five IQ&#xAE; Battery 5Ps could earn $6,250 upfront. Additionally, homeowners in all other utility territories are eligible for an upfront incentive of $200/kWh, capped at $5,000 per site. Homeowners who install five IQ Battery 5Ps can earn up to $5,000 upfront.

ENPH

Enphase Energy  Announces Homeowners In All Of New York's Major Investor-Owned Electric Utility Service Territories Who Install Enphase IQ Batteries Can Now Qualify To Enroll In The NYSERDA New York Battery Incentive Program

Press Releases

Quantum-Si to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Quantum-Si and Researchers to Showcase Next-Generation Protein Sequencing™ at US HUPO 2025

Quantum-Si's Customers and Researchers to Showcase Next-Generation Protein Sequencing™ at AGBT 2025

Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Power Metallic (TSXV: PNPN) Uses AI to Revolutionize Mining – Big Discoveries & More Tech Stocks Inside!

Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics Research

Quantum-Si Begins Shipping Platinum® Pro, Advancing Accessibility in Next-Gen Protein Sequencing™

Quantum-Si to Report First Quarter 2025 Financial Results on May 15, 2025

Dr. Gloria Sheynkman from the University of Virginia to Present Pioneering Research utilizing Quantum-Si's Next-Gen Protein Sequencing™ Platform in Upcoming Nature Webinar on May 15

Comments

Quantum-Si

Quantum-Si (QSI) Options

Quantum-Si (NASDAQ:QSI) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL